June 2026– date –
-
CordenPharma Announces Multi-Million Dollar Expansion of Oligonucleotide Manufacturing to Meet Soaring Demand for Nucleic Acid-Based Medicines
Pharmaceutical Technology Europe Overview CordenPharma announced a multi-million dollar investment to significantly expand its oligonucleotide manufacturing capacity across its global network. This strategic expansion aims to meet the in... -
Neuron Reports Novel Small Molecule Temporarily Opens Blood-Brain Barrier, Significantly Enhancing CNS Drug Delivery Preclinically
Neuron USA Overview A research paper in Neuron presented compelling preclinical data for a novel small molecule designed to temporarily and reversibly open the blood-brain barrier (BBB). This groundbreaking technology holds the potential... -
Pfizer Seagen Initiates Global Phase 3 Trial for ADC ‘PF-XXX’ in Platinum-Resistant Ovarian Cancer
Clinical Trials Arena USA Overview Pfizer Seagen has initiated a global Phase 3 clinical trial for its investigational antibody-drug conjugate (ADC), 'PF-XXX,' in patients with platinum-resistant ovarian cancer. The trial aims to evaluat... -
Novel AAV Capsid Designs for Gene Therapy Highlighted at ASGCT 2026, Improving Tissue Tropism and Immunogenicity
Gene Therapy News USA Overview The American Society of Gene and Cell Therapy (ASGCT) 2026 annual meeting highlighted several presentations on innovative adeno-associated virus (AAV) capsid designs. These new designs aim to enhance the ov... -
Nature Biotechnology Reports Novel Therapeutic Modality of Circular RNA for Cancer Treatment
Nature Biotechnology Unknown Overview A groundbreaking study published in Nature Biotechnology explores the therapeutic potential of engineered circular RNA molecules in cancer treatment. The research demonstrates that specific circular ... -
WuXi Biologics Completes and Prepares for Operation of New Antibody-Drug Conjugate (ADC) Manufacturing Facility
WuXi Biologics Press Release China Overview WuXi Biologics announced the successful completion and readiness for operation of its new integrated Antibody-Drug Conjugate (ADC) manufacturing facility. This expansion significantly enhances ... -
EMA Confirms Acceptance of Marketing Authorization Application for Novel Early Alzheimer’s Drug Candidate
PharmaNews Europe Europe Overview The European Medicines Agency (EMA) has confirmed acceptance of a Marketing Authorization Application (MAA) for a novel drug candidate targeting early Alzheimer's disease. The application includes pivota... -
FDA Grants Fast Track Designation to Investigational Gene Therapy for Rare Inherited Eye Disease
FDA Press Release USA Overview The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to an investigational gene therapy for a serious rare inherited eye disease. This designation aims to facilitate development an... -
Samsung Biologics Secures Multi-Year mRNA Vaccine CDMO Partnership with Major Pharma, Leading Market Expansion
Business Korea South Korea Overview Samsung Biologics has reportedly secured a multi-year contract for large-scale mRNA vaccine manufacturing with a global pharmaceutical company. This new partnership further solidifies Samsung Biologics... -
Lonza Significantly Expands Biologics Manufacturing Capacity by Over 200,000 Liters with New Swiss Facility
Lonza Press Release Switzerland Overview Lonza announced the operational launch of a state-of-the-art new facility in Visp, Switzerland, significantly expanding its biopharmaceutical manufacturing capabilities. This expansion adds over 2...
